vizimpro 45 mg 30 tabs
فيزيمبرو 45 مجم 30 قرص
dacomitinibThe published official price. Pharmacies may differ slightly.
- Strength
- 45 mg
- Form
- tablet
- Manufacturer
- pfizer
- Route
- oral.solid
The medical information below is guidance and may be incomplete or wrong. Do not change your medicine or dose based on it — ask a pharmacist or doctor.
Uses
Indicated as first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletion or exon 21 L858R substitution mutations as confirmed by an approved diagnostic test.
Do not use if
No contraindications are listed in the FDA label. Use with caution in patients with hepatic impairment.
Side effects
The most frequent adverse reactions (greater than 20%) include diarrhoea, rash, paronychia, stomatitis, decreased appetite, dry skin, and weight loss. Serious events include interstitial lung disease and severe dermatological reactions.
Warnings
Permanently discontinue if interstitial lung disease (ILD) or pneumonitis is confirmed. Withhold and dose-reduce for severe diarrhoea or dermatological toxicity. May cause foetal harm; effective contraception is required. Monitor for ocular toxicity.
How it works
Dacomitinib is a second-generation irreversible inhibitor of the pan-EGFR family (EGFR/HER1, HER2, and HER4) and selected EGFR-activating mutations. It covalently binds to the kinase domain ATP-binding site, permanently blocking downstream signalling that drives NSCLC tumour proliferation.
Storage
Store at 20–25°C (68–77°F); excursions permitted between 15–30°C (59–86°F). Store in original packaging.